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REVIEW

BTK/ITK dual inhibitors: Modulating immunopathology
and lymphopenia for COVID-19 therapy
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Abstract
Bruton’s tyrosine kinase (BTK) signaling is involved in innate immune responses and regulates
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the production of proinflammatory cytokines that can contribute to COVID-19 immunopathol-
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ogy. Clinical trials with BTK inhibitors in COVID-19 treatment have been proposed, and previous
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studies have attempted to investigate the therapeutic effects of ibrutinib and underlying mechanisms in treating viral pneumonia. These attempts, however, did not consider potential off target
effect of BTK inhibitors on T cell differentiation, function, and survival, which may be beneficial in
treatment for COVID-19. Here, we summarize the current knowledge of BTK/IL-2-inducible T-cell
kinase (ITK) signaling in immunopathology and lymphopenia and discuss the potential of BTK/ITK
dual inhibitors such as ibrutinib in modulating immunopathology and lymphopenia, for COVID-19
therapy.
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1

sera of patients admitted to the intensive care unit in Wuhan, China.1

INTRODUCTION

An overrepresentation of proinflammatory macrophages has been
Prior to the end of 2019, severe acute respiratory syndrome (SARS)

observed in the bronchoalveolar lavage (BAL) of severe cases com-

was a specific term referring to SARS-coronavirus (SARS-CoV)-

pared with mild cases,2 and elevated IL-6 in the sera is correlated with

induced respiratory disease. In December 2019, a cluster of SARS-

higher mortality.3 Lymphopenia and increased number of blood neu-

like pneumonia cases emerged in Wuhan, China. The etiologic agent

trophils are associated with severe and fatal COVID-19.4 These obser-

was later determined to be a novel beta-coronavirus and termed

vations suggest that targeting the host’s immune response including

SARS-CoV-2, while the associated disease was named coronavirus dis-

those leading to cytokine release syndrome (CRS) may be beneficial

ease of 2019 (COVID-19). SARS-CoV-2 is the third respiratory coro-

in treating immunopathology and the associated severe symptoms of

navirus to have caused an outbreak in the last 2 decades, along with

the infection (Fig. 1). We write here to draw attention to lymphope-

SARS-CoV that emerged in 2002 and Middle East respiratory syn-

nia and the potential of modulating T cells through targeting IL-2-

drome (MERS)-CoV that emerged in 2012. The majority of COVID-

inducible T-cell kinase (ITK) using Bruton’s tyrosine kinase (BTK)/ITK

19 cases are classified as mild to moderate. However, the disease can

dual inhibitors being evaluated for COVID-19 therapy.

progress to severe pneumonia, acute respiratory distress syndrome
(ARDS), and multiorgan failure, most of which are fatal.1 Patients with
COVID-19 display a dysregulated immune response. Elevated levels
of the proinflammatory cytokines and chemokines were observed in

2
IMMUNE THERAPIES TARGETING CRS IN
COVID-19: BTK INHIBITORS IN THE ARENA
Immune therapies targeting the COVID-19-associated cytokine storm

Abbreviations: ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage;
BTK, Bruton’s tyrosine kinase; CLL, chronic lymphocytic leukemia; COVID-19, coronavirus
disease of 2019; CRS, cytokine release syndrome; US FDA, United States Food and Drug
Administration; ITK, IL-2-Inducible T-cell kinase; MCL, mantle cell lymphoma; MERS, Middle
East respiratory syndrome; SARS, severe acute respiratory syndrome; SARS-CoV,
SARS-coronavirus; UTR, untranslated region.
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are currently being explored. Drugs that have already been approved
by the United States Food and Drug Administration (US FDA) would
be advantageous during this process as they would be easier to repurpose. Tocilizumab, a monoclonal antibody that blocks IL-6 signaling, is
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F I G U R E 1 Potential of BTK/ITK inhibitors for attenuating immunopathology and lymphopenia in COVID-19. SARS-CoV-2 infection in the
lungs set off proinflammatory cytokine production by lung cells and immune cells such as macrophages and neutrophils. Cytokine release syndrome further engages pulmonary and vascular tissue damages, leukocyte recruitment, T cell activation, and other cytotoxic immune responses. T
cells are possible targets of SARS-CoV-2 infection. Infected and over reactive T cells may be prompted toward apoptosis and cytolysis, resulting in
infection-induced lymphopenia. BTK/ITK inhibitors may function to down-regulate proinflammatory cytokine production by innate immune populations and reduce cytotoxic T cell death while sustaining virus-specific effector T cell function, therefore exhibit therapeutic functions against
immunopathology and lymphopenia. Solid-line arrows indicate known functions and dashed-line arrows indicate functions awaiting investigation

US FDA approved for treatment of rheumatoid arthritis and CRS. In

TLR/BTK pathway signals through the downstream NF-𝜅B, which

early February 2020, a preliminary study in China using tocilizumab

is up-regulated in proinflammatory macrophages that dominate the

along with routine treatment, on 21 severe and critical COVID-19

airways of severe COVID-19 patients compared with mild.2 Ex vivo

results.5

And in the US,

analysis of macrophages from severe COVID-19 patients found higher

Roche initiated a randomized, double-blind, placebo-controlled,

levels of BTK phosphorylation and higher IL-6 production at resting

multicenter phase III trial of tocilizumab in severe COVID-19 patients

state and when stimulated with a TLR7/8 agonist compared with the

(NCT0432061), starting on April 3, 2020. The encouraging results

healthy controls.7 Furthermore, activation of the NLRP3 inflamma-

of the tocilizumab trial in China also motivates assessments of ther-

some requires BTK to convert pro-IL-1𝛽 into its active form.6 Based on

apeutic strategies targeting the expression, receptor binding, and

the role of BTK in the production of inflammatory cytokines, clinical

downstream signaling of proinflammatory cytokines such as IL-6,

trials for the selective BTK inhibitors acalabrutinib and zanubrutinib

IL-1, TNF-𝛼, type I IFN, and IL-17A. BTK is highly expressed in B cells,

on COVID-19 have been initiated by AstraZeneca (Acalabrutinib:

but is also known to be involved in signaling pathways of multiple

NCT04346199) and BeiGene (Zanubrutinib: NCT04382586), respec-

TLRs, macrophages, and dendritic cells leading to induction of proin-

tively. Furthermore, a small off-label clinical study of severe COVID-19

flammatory cytokines, including the antiviral cytokine IFN-𝛽.6 The

patients treated with acalabrutinib for 10–14 days found the levels of

patients, showed encouraging therapeutic
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IL-6 in serum decreased during this time.7 By the end of treatment, 8

the viral Nucleocapsid, 5′ UTR, or Envelope genes).12,13 Despite the

out of 11 and 2 out of 8 patients that began on supplemental oxygen

apparent lack of viral genome replication, the SARS-CoV-2 nucleocap-

or mechanical ventilation, respectively, had been discharged on room

sid protein can persist within T cells up to 24 h postinfection13 ; and

air.7

In clinical practice, acalabrutinib is US FDA approved for treat-

viral particles could be observed via electron microscopy in SARS-CoV-

ing chronic lymphocytic leukemia (CLL), and zanubrutinib received

2-infected primary PBMCs (from healthy donors) in CD4+ T cells but

accelerated approval for treating mantle cell lymphoma (MCL).

not CD8+ T cells, at 48 h post in vitro infection.12 Given that this was
observed with PBMCs infected in vitro, further studies are required
to determine whether this represents a true preference in COVID-19.

3
DYSREGULATED T LYMPHOCYTES IN
SEVERE COVID-19
A robust and balanced adaptive immune response is important for
both viral clearance and limiting immunopathology. SARS-CoV-2
infection however triggers significant lymphocyte apoptosis, as
revealed by postmortem examinations of patients succumbed to
fatal COVID-19.8 In addition to the lymphopenia observed in severe
COVID-19 cases, there is also evidence suggesting T cell dysfunction
positively associated with the severity of COVID-19.9,10 Moreover,
delayed development of an adaptive immune response was associated
with mortality during SARS-CoV outbreak during 2002–2004.11 An

Although the consequences of T cell infection by SARS-CoV-2 have not
been investigated at this time, MERS-CoV has been reported to be able
to infect and induce apoptosis of human T cells, with a preference for
CD4+ over CD8+ T cells.14 Lymphopenia is positively associated with
severity and fatality of COVID-19 cases,4 and there is a possibility that
virus-induced apoptosis may be a potential explanation. It should be
stressed that at the time of writing this article, the consequences of
viral entry into human T cells is unknown. However, although potential SARS-CoV-2 infection of T cells is a fascinating finding, much more
investigation is required to get a better understanding of the mechanism of its entry, consequences on T cell function, and its physiologic
impact in COVID-19 patients.

increased frequency of exhausted CD8+ T cells and reduced frequency
of functional cytotoxic CD8+ T cells in the peripheral blood of COVID19 patients have been reported.9 In addition, a reduced proportion
of IFN-𝛾 + and TNF-𝛼 + CD4+ T cells, coinciding with CD8+ T cells
expressing increased levels HLA-DR and TIGIT, has been reported
in severe cases.9 These activation and exhaustion phenotypes of T
cells were mainly observed in PBMCs from COVID-19 patients. Single
cell RNA sequencing of cells in the BAL suggests reduced frequency
of CD8+ T cells among the total immune cell population in severe
COVID-19 patients compared with the mild cases.2 Mild cases had
a highly expanded effector CD8+ T cells in the airway, with a more
diverse T cell repertoire. By contrast, there is far less expansion and
diversity of CD8+ T cells in the BAL of severe patients.2 It is not
yet clear whether this represents delayed kinetics of the adaptive
response or reduced survival of the highly activated effector CD8+
T cells. The functional evaluation of immune cells in the respiratory
system, in particular, lymphocyte activation and function as identified by biomarkers at protein level and functional assays awaits
further investigation. Regardless, current data suggest that T cell
dysfunction may be a contributing factor in COVID-19. Clinical trials
targeting lymphocytes are ongoing or have been proposed, including
IL-7 treatment in lymphopenic COVID-19 patients (NCT04379076,
NCT04426201) and low-dose IL-2 treatment to expand Treg cells and
limit immunopathology (NCT04357444).

5
POTENTIAL OF BTK/ITK DUAL
INHIBITORS FOR TARGETING CRS AND
PROMOTING T CELL FUNCTION
Given this backdrop, targeting molecules that play critical signaling
functions in T lymphocytes, ideally those that preferentially regulate
T cell apoptosis and exhaustion over activation, may be a potential
strategy for treating patients with severe COVID-19. ITK is highly
expressed in T cells, and regulates the activation and function of both
CD4+ and CD8+ T cells, including cytokine production and cytotoxic
function.15 In addition to acalabrutinib and zanubrutinib, ibrutinib is
also a US FDA-approved BTK inhibitor, but is less specific as it also
inhibits ITK and TEC kinases, both of which are highly expressed in T
cells. Ibrutinib has been approved for treating CLL, MCL, chronic graftversus-host disease, and others.
High expression of Fas coinciding with increased lymphocyte
apoptosis has been observed in the lymph nodes and spleens of
patients that died of COVID-19 compared with the healthy controls.8
Along with alterations in B cells, CLL patients treated with ibrutinib
displayed an increase in total number of T cells, which is not seen in
patients treated with the more specific acalabrutinib.16 The observed
accumulation of T cells may be due to a decrease in activation-induced
cell death, which has been shown to be a result of the ITK signalingmediated up-regulation of FasL, which promotes activation-induced

4
SARS-CoV-2 INFECTION IN T
LYMPHOCYTES

T cell death. Indeed, human T cells stimulated in vitro in the presence
of ibrutinib express lower levels of FasL and undergo apoptosis at
a lower rate.16 This is consistent with findings of the mouse models

This speculation is further supported by recent findings that SARS-

of OVA-induced allergic asthma where inhibition of ITK resulted in

CoV-2 is able to enter human T cells, although replication inside T cells

an increase in total CD4+ T cells coinciding with a decreased T cell

was not observed (as determined via RT-qPCR with probes targeting

apoptosis in the spleen and draining lymph node.17
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Several lines of evidence suggest a Th1 response is critical in controlling respiratory coronavirus infection. Convalescent COVID-19
patients display predominately a Th1-polarized SARS-CoV-2-specific
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memory T cell response.18–21 Mice vaccinated with virus replicon
particles expressing SARS-CoV or MERS-CoV N protein resulted in
IFN-𝛾 + CD4+ T cell-dependent protection from challenge,22 whereas
mouse models of SARS-CoV infection found the recruitment of
IFN-𝛾 + CD4+ cells to be an important event in controlling virus
replication and lung immunopathology during primary infection.23
Ibrutinib can irreversibly bind to ITK, but does not affect Th1 and
CD8+ T cell effector function, likely because of the expression of
redundant Tec family kinases, such as RLK, which is not targeted
by ibrutinib.24 Furthermore, ibrutinib can functionally restore
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leukemia/listeriosis.24
In a mouse model of ARDS induced by lethal dose infection with
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reducing the production of inflammatory cytokines, lung tissue damage, and mortality.25 In patients who were on ibrutinib treatment
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for Waldenstrom’s Macroglobulinemia and recently diagnosed with
COVID-19 (6 patients reported), 5 out of 6 continued with regular
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dosage of ibrutinib and developed very mild COVID-19 symptoms,
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whereas 1 out of 6 held ibrutinib after contracting COVID-19 needed
to be hospitalized because of severe symptoms and had to restart ibrutinib treatment; eventually, all recovered from the infection.26 Similarly, in patients who were on BTK inhibitor treatment for CLL, 2 (out
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